ClinicalTrials.gg
CompletedNCT02241759Updated Feb 16, 2015

Study of the Electrocardiographic Effects of TA-8995

A Phase 1 interventional study of TA-8995 and Moxifloxacin in Dyslipidaemia, sponsored by Xention Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-16.

Sponsored by Xention Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.

Enrollment
5th of 14
136 · median 116
Started
2014
the only one that year
Phase 1
5 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
4 of 14
Xention Ltd

Among the 14 studies testing TA-8995 in Dyslipidemias, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 4th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About TA-8995

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing TA-8995 in Dyslipidemias, or all of them as a file.
02

Study summary

A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.

03

Conditions studied

  • Dyslipidaemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or females of non-child bearing potential

Exclusion criteria

Exclusion Criteria:

  • Receiving any other drug therapy
  • medical history
  • Abnormal ECGs or vital signs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    TA-8995

    Single oral dose of 150mg TA-8995

    Drug: TA-8995

  • Experimental
    Placebo

    Single oral dose of placebo to TA-8995

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Single open-label oral dose of 400mg moxifloxacin

    Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in QT interval corrected for heart rate (QTc) for TA-8995 versus placebo

    Time frame: 4 days

Secondary outcomes

  1. Relationship between plasma levels of TA-8995 and the QTcF effect

    Time frame: 4 days

07

Study locations

1 site
  • Covance Clinical Research Unit Ltd
    Leeds, LS2 9LH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Sep 16, 2014
Start
Aug 2014
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Last update
Feb 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02241759
Lead sponsor
Xention Ltd
Responsible party
Sponsor
First posted
Sep 16, 2014
Start date
Aug 2014
Primary completion
Nov 2014
Completion
Dec 2014
Last update
Feb 16, 2015

Study contacts

Ashley Brooks
principal investigator · Covance

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion